Highlights Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
65.19 ^USD	-0.58%		-1.17%	+3.81%

05-08	Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-25	Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	03-04	CI
Vaxcyte Q4 Loss Widens	02-27	MT
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Aged 50 and Older	01-29	CI
Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise	01-04	CI
Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases	12-04	CI
Vaxcyte Exercises Option for Manufacturing Rights Agreement With Sutro Biopharma; Sutro Shares Jump Premarket	11-28	MT
Vaxcyte Exercises Option for Manufacturing Rights Agreement With Sutro Biopharma	11-27	MT
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults	11-09	CI
Vaxcyte, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06	CI
Vaxcyte Says FDA Approves Investigational New Drug Application for Invasive Pneumococcal Disease Vaccine Candidate	19/10/23	MT
Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults	19/10/23	CI
Vaxcyte, Lonza Sign Vaccine Manufacturing Agreement	16/10/23	MT
Lonza, Vaxcyte Expand Partnership With New Vaccine Manufacturing Facility	16/10/23	MT
Vaxcyte, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23	CI
VAXCYTE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	08/05/23	AQ
Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	08/05/23	CI
Vaxcyte, Inc. announces positive results from the VAX-24 Phase 2 study	17/04/23	CI
Vaxcyte, Inc. Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	30/03/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Highlights

Filters